Sign in

David Aslam

Senior Equity Research Analyst at Piper Sandler

David Aslam is a Senior Equity Research Analyst at Piper Sandler, specializing in coverage of healthcare and pharmaceutical companies, including AbbVie, Merck, and DaVita. Known for his incisive research and targeted sector analyses, Aslam regularly engages with executive management on earnings calls and has established a strong track record of timely investment calls and respected forecasts. He began his career in equity research and transitioned to Piper Sandler, where he has become a key resource for institutional clients seeking insights into the pharma and healthcare landscape. Professionally, Aslam holds FINRA registrations and securities analyst credentials, underscoring his expertise and commitment to regulatory standards in financial research.

David Aslam's questions to AbbVie (ABBV) leadership

Question · Q3 2025

David Aslam inquired about the uptake of Violev in the Parkinson's franchise, competitive dynamics against Imapgo, and the sales potential and role of tevapadon as both monotherapy and adjunctive therapy.

Answer

EVP and CCO Jeff Stewart and EVP, Research and Development, and CSO Roopal Thakkar highlighted Violev's strong global ramp-up, 24-hour coverage, and high in-play capture rate against competitors due to superior disease stability and reduced oral therapy needs. Roopal Thakkar detailed tevapadon's potential as a once-daily complement to Violev, emphasizing its efficacy and favorable safety profile compared to existing oral generics.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts